Synthesis of SMT022357 enantiomers and in vivo evaluation in a Duchenne muscular dystrophy mouse model

Following on from ezutromid, the first-in-class benzoxazole utrophin modulator that progressed to Phase 2 clinical trials for the treatment of Duchenne muscular dystrophy, a new chemotype was designed to optimise its physicochemical and ADME profile. Herein we report the synthesis of SMT022357, a se...

Descripción completa

Detalles Bibliográficos
Autores principales: Babbs, Arran, Berg, Adam, Chatzopoulou, Maria, Davies, Kay E., Davies, Stephen G., Edwards, Benjamin, Elsey, David J., Emer, Enrico, Figuccia, Aude L.A., Fletcher, Ai M., Guiraud, Simon, Harriman, Shawn, Moir, Lee, Robinson, Neil, Rowley, Jessica A., Russell, Angela J., Squire, Sarah E., Thomson, James E., Tinsley, Jonathon M., Wilson, Francis X., Wynne, Graham M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pergamon Press 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369641/
https://www.ncbi.nlm.nih.gov/pubmed/32713969
http://dx.doi.org/10.1016/j.tet.2019.130819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369641/
https://www.ncbi.nlm.nih.gov/pubmed/32713969
http://dx.doi.org/10.1016/j.tet.2019.130819

Ejemplares similares